---
title: Sufentanil as Adjuvant of Balanced Anesthesia
nct_id: NCT03868111
overall_status: COMPLETED
phase: NA
sponsor: Kangbuk Samsung Hospital
study_type: INTERVENTIONAL
primary_condition: Anesthesia
countries: South Korea
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03868111.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03868111"
ct_last_update_post_date: 2020-06-04
last_seen_at: "2026-05-12T06:33:58.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Sufentanil as Adjuvant of Balanced Anesthesia

**Official Title:** Comparison Between Sufentanil and Remifentanil as General Anesthetic Adjuvant

**NCT ID:** [NCT03868111](https://clinicaltrials.gov/study/NCT03868111)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 66
- **Lead Sponsor:** Kangbuk Samsung Hospital
- **Conditions:** Anesthesia
- **Start Date:** 2019-11-04
- **Completion Date:** 2020-01-12
- **CT.gov Last Update:** 2020-06-04

## Brief Summary

The aim of the study was to compare the efficacy and safety between sufentanil and remifentanil as an adjuvant of balanced general anesthesia.

## Detailed Description

The investigators hypothesized that sufentanil would reduce postoperative pain than remifentanil without prolonging recovery times in minor laparoscopic surgery when administered equivalent antinociceptive doses during surgery. Intraoperative opioid administration for equivalent nociception-antinociception balance could be achieved via surgical pleth index (SPI)-guided analgesia. This study was designed to compare the efficacy and safety between sufentanil and remifentanil as an adjuvant of balanced anesthesia in patients undergoing laparoscopic cholecystectomy under SPI-guided opioid administration.

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients aged between 19 and 65 years
* Patients with American Society of Anesthesiologists physical status I or II
* Patients scheduled for elective laparoscopic cholecystectomy under balanced general anesthesia for benign cholecystic diseases
* Patients obtaining written informed consent

Exclusion Criteria:

* Patients with asthma or hypertension
* Patients with an inability to express their pain accurately
* Patients with an inability to understand the pain scale
* Patients with chronic abdominal pain or chronic pain syndrome
* Patients who required to convert to laparotomy from laparoscopic surgery
* Patients who required to receive incidental lower abdominal procedures owing to adhesion, injury, or other incidental findings at the lower abdominal cavity
* Patients with a history of drug or alcohol abuse
* Pregnant women
```

## Arms

- **Sufentanil** (EXPERIMENTAL) — Balanced anesthesia is maintained with 1 MAC desflurane and sufentanil during laparoscopic cholecystectomy.
- **Remifentanil** (EXPERIMENTAL) — Balanced anesthesia is maintained with 1 MAC desflurane and remifentanil during laparoscopic cholecystectomy.

## Interventions

- **Sufentanil** (DRUG) — The infusion rate of sufentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.
- **Remifentanil** (DRUG) — The infusion rate of remifentanil is adjusted to achieve a surgical pleth index of 20-50 throughout the operative time.

## Primary Outcomes

- **Postoperative wound pain score** _(time frame: 10 minutes after surgery)_ — The pain score is evaluated by 10 point visual analogue scale at post-anesthesia care unit. The visual analogue scale is presented as a 10-cm line with verbal descriptors indicating "no pain" and "pain as bad as it could be". The visual analogue scale ranges from 0 to 10, representing minimum and maximum pain levels, respectively.

## Locations (1)

- Kangbuk Samsung Hospital, Seoul, South Korea

## Recent Field Changes (last 30 days)

- `armsInterventions.arms` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.kangbuk samsung hospital|seoul||south korea` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03868111.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03868111*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*